secwatch.observer — SEC 8-K summary
======================================

Issuer:     Co-Diagnostics, Inc. (CODX)
CIK:        0001692415
Form:       8-K
Filed at:   2022-03-24T23:59:59+00:00
Accession:  0001493152-22-007660
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Co-Diagnostics reports FY2021 revenue $97.9M, EPS $1.23; guides Q1 FY2022 revenue $21-22M
--------------------------------------------------------------------------------

- Revenue $97.9M, +$23.3M YoY; net income $36.7M ($1.23 diluted EPS) vs $42.5M ($1.52) in 2020.
- Adjusted EBITDA $52.1M, up from $45.3M in 2020; cash & securities $89.9M at Dec 31, 2021.
- Q1 FY2022 guidance: revenue $21-22M, diluted EPS $0.17-0.20, shares 32.4M.
- Gross profit $86.3M (88.2% margin); operating income $46.1M on record revenue.
- 2021 highlights: at-home PCR platform, acquisitions of Idaho Molecular & Advanced Conceptions, CDSCO clearance for ABC test in India.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692415/000149315222007660/0001493152-22-007660-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692415/000149315222007660/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-007660

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer